Protein-based tumor molecular imaging probes

Amino Acids

Volumn 41, Issue 5, 2011, Pages 1013-1036

  Lin, Xin ^a   Xie, Jin ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Antibody; Human epidermal growth factor receptor (HER); Tumor targeting; Vascular endothelial growth factor (VEGF)

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALVESPIMYCIN; CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD20 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD52 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPITHELIAL CELL ADHESION MOLECULE; ETARACIZUMAB; FATTY ACID BINDING PROTEIN; FIBRONECTIN; IMMUNOGLOBULIN G ANTIBODY; LIPOCORTIN 5; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SCAFFOLD PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOMATOMEDIN C RECEPTOR; TENASCIN; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ALPHA CHAIN; ANTINEOPLASTIC ACTIVITY; BETA CHAIN; BREAST CANCER; COLON CANCER; DIAGNOSTIC ACCURACY; DRUG EFFICACY; EPITHELIUM TUMOR; GLIOMA; HUMAN; ISOTOPE LABELING; LIGAND BINDING; METASTASIS; MOLECULAR IMAGING; MOLECULAR PROBE; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PROCESSING; RECEPTOR AFFINITY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TUMOR; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855221646     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-010-0545-z     Document Type: Review

References (217)

1. Abel-Santos E, Scott CP, Benkovic SJ (2003) Use of inteins for the in vivo production of stable cyclic peptide libraries in E coli. Methods Mol Biol 205:281-294
2. Adams GP, Schier R (1999) Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods 231(1-2):249-260 (Pubitemid 30394738)
3. Adams GP, McCartney JE, Tai MS et al (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53(17):4026-4034 (Pubitemid 23267706)
4. Adams GP, Schier R, McCall AM et al (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77(9):1405-1412 (Pubitemid 28190739)
5. Allan SM, Dean CJ, Eccles S, Sacks NP (1994) Clinical radioimmunolocalization with a rat monoclonal antibody directed against c-erbB-2. Cell Biophys 24-25:93-98
6. Antoniw P, Farnsworth AP, Turner A et al (1996) Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br J Cancer 74(4):513-524 (Pubitemid 26279044)
7. Arteaga C (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30(3 Suppl 7):3-14 (Pubitemid 36828623)
8. Ayers B, Blaschke UK, Camarero JA, Cotton GJ, Holford M, Muir TW (1999) Introduction of unnatural amino acids into proteins using expressed protein ligation. Biopolymers 51(5):343-354 (Pubitemid 30117294)
9. Backer MV, Levashova Z, Patel V et al (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 13(4):504-509 (Pubitemid 46559824)
10. Beckett D, Kovaleva E, Schatz PJ (1999) A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci 8(4):921-929 (Pubitemid 29165423)
11. Beckman RA, Weiner LM, Davis HM (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109(2):170-179 (Pubitemid 46106231)
12. Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25(2):201-212 (Pubitemid 28130048)
13. Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23(4):201-208 (Pubitemid 34260936)
14. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401-410 (Pubitemid 37328844)
15. 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med 47(10):1707-1716 (Pubitemid 47545038)
16. Berteau O, Guillot A, Benjdia A, Rabot S (2006) A new type of bacterial sulfatase reveals a novel maturation pathway in prokaryotes. J Biol Chem 281(32):22464-22470
17. Blankenberg FG, Katsikis PD, Tait JF et al (1999) Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 40(1):184-191 (Pubitemid 29044190)
18. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312(5995):643-646 (Pubitemid 15218335)
19. Brustad EM, Lemke EA, Schultz PG, Deniz AA (2008) A general and efficient method for the site-specific dual-labeling of proteins for single molecule fluorescence resonance energy transfer. J Am Chem Soc 130(52):17664-17665
20. Cai W, Chen X (2006) Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6(5):407-428 (Pubitemid 44377776)
21. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X (2006a) In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res 66(19):9673-9681 (Pubitemid 44623667)
22. Cai W, Chen K, Mohamedali KA et al (2006b) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47(12):2048-2056 (Pubitemid 47544993)
23. Cai W, Chen K, He L, Cao Q, Koong A, Chen X (2007a) Quantitative PET of EGFR expression in xenograft-bearing mice using 64Culabeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34(6):850-858 (Pubitemid 46798960)
24. Cai W, Ebrahimnejad A, Chen K et al (2007b) Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 34(12):2024-2036 (Pubitemid 350212123)
25. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 48(2):304-310 (Pubitemid 47555358)
26. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438(7070):932-936 (Pubitemid 43093958)
27. Carrico IS, Carlson BL, Bertozzi CR (2007) Introducing genetically encoded aldehydes into proteins. Nat Chem Biol 3(6):321-322 (Pubitemid 46789266)
28. Casalini P, Iorio MV, Galmozzi E, Menard S (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200(3):343-350 (Pubitemid 39006925)
29. Casey JL, King DJ, Chaplin LC et al (1996) Preparation, characterization and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab0 fragments. Br J Cancer 74(9):1397-1405 (Pubitemid 26370730)
30. Casey JL, Napier MP, King DJ et al (2002) Tumour targeting of humanised cross-linked divalent-Fab0 antibody fragments: a clinical phase I/II study. Br J Cancer 86(9):1401-1410 (Pubitemid 34548060)
31. Chames P, Baty D (2000) Antibody engineering and its applications in tumor targeting and intracellular immunization. FEMS Microbiol Lett 189(1):1-8 (Pubitemid 30456238)
32. Chang CP, Zhao J, Wiedmer T, Sims PJ (1993) Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine. J Biol Chem 268(10):7171-7178 (Pubitemid 23105607)
33. Charalambous A, Andreou M, Skourides PA (2009) Intein-mediated site-specific conjugation of quantum dots to proteins in vivo. J Nanobiotechnol 7:9
34. Chen P, Mrkobrada M, Vallis KA et al (2002) Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells. Nucl Med Biol 29(6):693-699 (Pubitemid 35266670)
35. Cohen S (1983) The epidermal growth factor (EGF). Cancer 51(10):1787-1791 (Pubitemid 13093942)
36. Colcher D, Goel A, Pavlinkova G, Beresford G, Booth B, Batra SK (1999) Effects of genetic engineering on the pharmacokinetics of antibodies. Q J Nucl Med 43(2):132-139 (Pubitemid 29318048)
37. Collingridge DR, Carroll VA, Glaser M et al (2002) The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62(20):5912-5919 (Pubitemid 35204754)
38. Colnot DR, Quak JJ, Roos JC et al (2000) Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41(12):1999-2010 (Pubitemid 32038689)
39. Comfurius P, Smeets EF, Willems GM, Bevers EM, Zwaal RF (1994) Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine. Biochemistry 33(34):10319-10324 (Pubitemid 24281797)
40. Connellan JM, Chung SI, Whetzel NK, Bradley LM, Folk JE (1971) Structural properties of guinea pig liver transglutaminase. J Biol Chem 246(4):1093-1098
41. Coussons PJ, Price NC, Kelly SM, Smith B, Sawyer L (1992) Factors that govern the specificity of transglutaminase-catalysed modification of proteins and peptides. Biochem J 282(Pt 3):929-930
42. Cuartero-Plaza A, Martinez-Miralles E, Rosell R, Vadell-Nadal C, Farre M, Real FX (1996) Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res 2(1):13-20
43. Cull MG, Schatz PJ (2000) Biotinylation of proteins in vivo and in vitro using small peptide tags. Methods Enzymol 326:430-440
44. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GA (1994) Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targeting tumours in the upper aerodigestive and respiratory tract. Nucl Med Commun 15(8):613-627 (Pubitemid 24259775)
45. Dean CJ, Eccles SA, Valeri M et al (1993) Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer. Cell Biophys 22(1-3):111-127
46. Dijkers EC, Kosterink JG, Rademaker AP et al (2009) Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50(6):974-981
47. Downward J, Yarden Y, Mayes E et al (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307(5951):521-527 (Pubitemid 14135812)
48. Dumont EA, Reutelingsperger CP, Smits JF et al (2001) Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 7(12):1352-1355 (Pubitemid 34007941)
49. Engfeldt T, Renberg B, Brumer H, Nygren PA, Karlstrom AE (2005) Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein. Chembiochem 6(6):1043-1050 (Pubitemid 40825345)
50. 99mTc- chelating mercaptoacetyl-glycyl-glycylglycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 34(5):722-733 (Pubitemid 46669355)
51. Evans TC Jr, Benner J, Xu MQ (1999) The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum. J Biol Chem 274(7):3923-3926
52. Fernandez A, Spitzer E, Perez R et al (1992) A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections. J Cell Biochem 49(2):157-165
53. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795-803 (Pubitemid 37328914)
54. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581-611 (Pubitemid 39099316)
55. Ferrara N (2005) The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS (94):209-231
56. Fields GB, Noble RL (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35(3):161-214 (Pubitemid 20126875)
57. Fishwild DM, O'Donnell SL, Bengoechea T et al (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14(7):845-851 (Pubitemid 26239182)
58. Folk JE (1983) Mechanism and basis for specificity of transglutaminase- catalyzed epsilon-(gamma-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol 54:1-56
59. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27-31
60. Fontana A, Spolaore B, Mero A, Veronese FM (2008) Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 60(1):13-28 (Pubitemid 350181164)
61. Francis RJ, Sharma SK, Springer C et al (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 87(6):600-607
62. Friedman M, Stahl S (2009) Engineered affinity proteins for tumour-targeting applications. Biotechnol Appl Biochem 53(Pt 1):1-29
63. Friedman M, Nordberg E, Hoiden-Guthenberg I et al (2007) Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 20(4):189-199 (Pubitemid 351321300)
64. Friedman M, Orlova A, Johansson E et al (2008) Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 376(5):1388-1402
65. Funaro A, Horenstein AL, Santoro P, Cinti C, Gregorini A, Malavasi F (2000) Monoclonal antibodies and therapy of human cancers. Biotechnol Adv 18(5):385-401
66. Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82(2):331-371 (Pubitemid 34654456)
67. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J (1989) Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst 81(21):1616-1625 (Pubitemid 19264044)
68. Graslund S, Eklund M, Falk R, Uhlen M, Nygren PA, Stahl S (2002) A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products. J Biotechnol 99(1):41-50 (Pubitemid 35229982)
69. Greenberg CS, Birckbichler PJ, Rice RH (1991) Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 5(15):3071-3077 (Pubitemid 21892867)
70. Gronemeyer T, Chidley C, Juillerat A, Heinis C, Johnsson K (2006) Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling. Protein Eng Des Sel 19(7):309-316 (Pubitemid 43999641)
71. Gronwall C, Jonsson A, Lindstrom S, Gunneriusson E, Stahl S, Herne N (2007a) Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J Biotechnol 128(1):162-183 (Pubitemid 44960520)
72. Gronwall C, Sjoberg A, Ramstrom M et al (2007b) Affibodymediated transferrin depletion for proteomics applications. Biotechnol J 2(11):1389-1398 (Pubitemid 350162260)
73. Gronwall C, Snelders E, Palm AJ, Eriksson F, Herne N, Stahl S (2008) Generation of Affibody ligands binding interleukin-2 receptor alpha/CD25. Biotechnol Appl Biochem 50(Pt 2):97-112 (Pubitemid 351809212)
74. Gross ME, Shazer RL, Agus DB (2004) Targeting the HER-kinase axis in cancer. Semin Oncol 31(1 Suppl 3):9-20 (Pubitemid 38543936)
75. Gunneriusson E, Nord K, Uhlen M, Nygren P (1999) Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng 12(10):873-878 (Pubitemid 29533112)
76. 99mTc-HYNIC-annexin V imaging of early tumor apoptosis in mice after single dose irradiation. J Exp Clin Cancer Res 28:136
77. Henning P, Magnusson MK, Gunneriusson E et al (2002) Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther 13(12):1427-1439
78. Herberman RB (2002) Cancer immunotherapy with natural killer cells. Semin Oncol 29(3 Suppl 7):27-30 (Pubitemid 34620432)
79. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027 (Pubitemid 46202320)
80. Hofer A, Saez JC, Chang CC, Trosko JE, Spray DC, Dermietzel R (1996) C-erbB2/neu transfection induces gap junctional communication incompetence in glial cells. J Neurosci 16(14):4311-4321 (Pubitemid 26243027)
81. Hofstra L, Liem IH, Dumont EA et al (2000) Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356(9225):209-212 (Pubitemid 30446976)
82. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126-1136 (Pubitemid 41486394)
83. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2(2):91-100 (Pubitemid 37328796)
84. Hsu AR, Cai W, Veeravagu A et al (2007) Multimodality molecular imaging of glioblastoma growth inhibition with vasculaturetargeting fusion toxin VEGF121/rGel. J Nucl Med 48(3):445-454 (Pubitemid 47604931)
85. Hu S, Shively L, Raubitschek A et al (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56(13):3055-3061
86. Hudson PJ (1999) Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 11(5):548-557 (Pubitemid 29462131)
87. Hudson PJ (2000) Recombinant antibodies: a novel approach to cancer diagnosis and therapy. Expert Opin Invest Drugs 9(6):1231-1242 (Pubitemid 30342611)
88. Hudson PJ, Kortt AA (1999) High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231(1-2):177-189 (Pubitemid 30394733)
89. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673-687 (Pubitemid 35283958)
90. Iwai H, Lingel A, Pluckthun A (2001) Cyclic green fluorescent protein produced in vivo using an artificially split PI-PfuI intein from Pyrococcus furiosus. J Biol Chem 276(19):16548-16554
91. Jayson GC, Zweit J, Jackson A et al (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94(19):1484-1493 (Pubitemid 35251753)
92. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069): 522-525 (Pubitemid 16052256)
93. Jones DH, Cellitti SE, Hao X et al (2010) Site-specific labeling of proteins with NMR-active unnatural amino acids. J Biomol NMR 46(1):89-100
94. Juillerat A, Gronemeyer T, Keppler A et al (2003) Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. Chem Biol 10(4):313-317 (Pubitemid 36516649)
95. Kamiya N, Abe H, Goto M, Tsuji Y, Jikuya H (2009) Fluorescent substrates for covalent protein labeling catalyzed by microbial transglutaminase. Org Biomol Chem 7(17):3407-3412
96. Kampmeier F, Ribbert M, Nachreiner T et al (2009) Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem 20(5):1010-1015
97. Karlstrom A, Nygren PA (2001) Dual labeling of a binding protein allows for specific fluorescence detection of native protein. Anal Biochem 295(1):22-30 (Pubitemid 32725022)
98. Keyt BA, Nguyen HV, Berleau LT et al (1996) Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271(10):5638-5646
99. Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, Kobayashi H (2007) In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 9(12):1021-1029 (Pubitemid 350255349)
100. Kramer-Marek G, Kiesewetter DO, Capala J (2009) Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 50(7):1131-1139
101. Kronqvist N, Lofblom J, Jonsson A, Wernerus H, Stahl S (2008) A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng Des Sel 21(4):247-255 (Pubitemid 351431053)
102. Langone JJ (1982) Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. Adv Immunol 32:157-252
103. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7(1):21-39
104. Li PC, Wang CR, Shieh DB et al (2008) In vivo photoacoustic molecular imaging with simultaneous multiple selective targeting using antibody-conjugated gold nanorods. Opt Express 16(23):18605-18615
105. Lin CW, Ting AY (2006) Transglutaminase-catalyzed site-specific conjugation of small-molecule probes to proteins in vitro and on the surface of living cells. J Am Chem Soc 128(14):4542-4543
106. Lin CR, Chen WS, Kruiger W et al (1984) Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 224(4651):843-848 (Pubitemid 14102458)
107. Lindahl T, Sedgwick B, Sekiguchi M, Nakabeppu Y (1988) Regulation and expression of the adaptive response to alkylating agents. Annu Rev Biochem 57:133-157
108. Lobato MN, Rabbitts TH (2004) Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr Mol Med 4(5):519-528 (Pubitemid 38961195)
109. Lovrinovic M, Seidel R, Wacker R et al (2003) Synthesis of proteinnucleic acid conjugates by expressed protein ligation. Chem Commun (Camb) (7):822-823 (Pubitemid 36461168)
110. Lundberg E, Hoiden-Guthenberg I, Larsson B, Uhlen M, Graslund T (2007) Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 319(1-2):53-63 (Pubitemid 46107467)
111. Lyakhov I, Zielinski R, Kuban M et al (2010) HER2- and EGFRspecific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem 11(3):345-350
112. Ma J, Cooney CL (2004) Application of vortex flow adsorption technology to intein-mediated recovery of recombinant human alpha1-antitrypsin. Biotechnol Prog 20(1):269-276 (Pubitemid 38204198)
113. Mankoff DA (2007) A definition of molecular imaging. J Nucl Med 48(6):18N-21N
114. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549-555 (Pubitemid 35223554)
115. Margison GP, Santibanez-Koref MF (2002) O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 24(3):255-266 (Pubitemid 34248691)
116. Mass RD (2004) The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58(3):932-940 (Pubitemid 38221153)
117. Mayer A, Tsiompanou E, O'Malley D et al (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 6(5):1711-1719 (Pubitemid 30305063)
118. Mease RC, Lambert C (2001) Newer methods of labeling diagnostic agents with Tc-99m. Semin Nucl Med 31(4):278-285 (Pubitemid 33027506)
119. Meers P, Mealy T (1993) Calcium-dependent annexin V binding to phospholipids: stoichiometry, specificity, and the role of negative charge. Biochemistry 32(43):11711-11721 (Pubitemid 23341451)
120. Miyake-Stoner SJ, Miller AM, Hammill JT et al (2009) Probing protein folding using site-specifically encoded unnatural amino acids as FRET donors with tryptophan. Biochemistry 48(25):5953-5962
121. Muir TW (2003) Semisynthesis of proteins by expressed protein ligation. Annu Rev Biochem 72:249-289 (Pubitemid 36930447)
122. Mume E, Orlova A, Larsson B et al (2005) Evaluation of ((4- hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem 16(6):1547-1555 (Pubitemid 41683137)
123. Muralidharan V, Muir TW (2006) Protein ligation: an enabling technology for the biophysical analysis of proteins. Nat Methods 3(6):429-438 (Pubitemid 43811554)
124. Muralidharan V, Cho J, Trester-Zedlitz M et al (2004) Domainspecific incorporation of noninvasive optical probes into recombinant proteins. J Am Chem Soc 126(43):14004-14012 (Pubitemid 39447077)
125. Myhre S, Henning P, Granio O et al (2007) Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector. Gene Ther 14(4):376-381 (Pubitemid 46231931)
126. Nagengast WB, de Vries EG, Hospers GA et al (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48(8):1313-1319 (Pubitemid 47242797)
127. Narula J, Acio ER, Narula N et al (2001) Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 7(12):1347-1352 (Pubitemid 34007940)
128. Niu G, Li Z, Cao Q, Chen X (2009) Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 36(9):1510-1519
129. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15(8):772-777 (Pubitemid 27329481)
130. Nord K, Gunneriusson E, Uhlen M, Nygren PA (2000) Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1M and taq DNA polymerase. J Biotechnol 80(1):45-54 (Pubitemid 30336349)
131. Nord K, Nord O, Uhlen M, Kelley B, Ljungqvist C, Nygren PA (2001) Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur J Biochem 268(15):4269-4277 (Pubitemid 32867311)
132. Nord O, Gustrin A, Nygren PA (2005) Fluorescent detection of betalactamase activity in living Escherichia coli cells via esterase supplementation. FEMS Microbiol Lett 242(1):73-79 (Pubitemid 40038422)
133. Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1):2-16 (Pubitemid 43199589)
134. Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H (2009) Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm 6(2):386-395
135. Orlova A, Nilsson FY, Wikman M et al (2006a) Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 47(3):512-519 (Pubitemid 46768494)
136. Orlova A, Magnusson M, Eriksson TL et al (2006b) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66(8):4339-4348
137. Orlova A, Tolmachev V, Pehrson R et al (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67(5):2178-2186 (Pubitemid 46424237)
138. Park H, Lee S, Chen L et al (2009) SERS imaging of HER2- overexpressed MCF7 cells using antibody-conjugated gold nanorods. Phys Chem Chem Phys 11(34):7444-7449
139. Pateisky N, Schatten C, Vavra N et al (1991) Lymphoscintigraphy using epidermal growth factor as tumour-seeking agent in uterine cervical cancer. Wien Klin Wochenschr 103(21):654-656
140. Pegg AE (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462(2-3):83-100
141. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223
142. Pluckthun A, Pack P (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3(2):83-105 (Pubitemid 27356788)
143. Ramakrishnan B, Boeggeman E, Manzoni M et al (2009) Multiple site-specific in vitro labeling of single-chain antibody. Bioconjug Chem 20(7):1383-1389
144. 99mTc- labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin. Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 40(5):768-775 (Pubitemid 29210750)
145. Reilly RM, Kiarash R, Cameron RG et al (2000) 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 41(3):429-438 (Pubitemid 30133961)
146. Ren G, Zhang R, Liu Z et al (2009) A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med 50(9):1492-1499
147. Ronnmark J, Hansson M, Nguyen T et al (2002) Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J Immunol Methods 261(1-2):199-211 (Pubitemid 34175229)
148. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715-725 (Pubitemid 47327396)
149. 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med 47(11):1813-1818 (Pubitemid 47545004)
150. Saga T, Endo K, Akiyama T et al (1991) Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a classswitched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 51(3):990-994
151. Sampath L, Kwon S, Ke S et al (2007) Dual-labeled trastuzumabbased imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 48(9):1501-1510 (Pubitemid 47397400)
152. Sandstrom K, Xu Z, Forsberg G, Nygren PA (2003) Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng 16(9):691-697 (Pubitemid 37314397)
153. Sato H, Ikeda M, Suzuki K, Hirayama K (1996) Site-specific modification of interleukin-2 by the combined use of genetic engineering techniques and transglutaminase. Biochemistry 35(40):13072-13080 (Pubitemid 26349457)
154. Schatten C, Pateisky N, Vavra N et al (1991) Lymphoscintigraphy with 123I-labelled epidermal growth factor. Lancet 337(8738):395-396
155. 99mTc-ethylenedicysteine- C225 monoclonal antibody. Anticancer Drugs 14(1):49-56 (Pubitemid 36177354)
156. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2):211-225
157. Schneider PM, Hung MC, Chiocca SM et al (1989) Differential expression of the c-erbB-2 gene in human small cell and nonsmall cell lung cancer. Cancer Res 49(18):4968-4971 (Pubitemid 19239327)
158. Schuhmacher J, Kaul S, Klivenyi G et al (2001) Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 61(9):3712-3717 (Pubitemid 32694984)
159. Schwarzer D, Cole PA (2005) Protein semisynthesis and expressed protein ligation: chasing a protein's tail. Curr Opin Chem Biol 9(6):561-569 (Pubitemid 41612183)
160. Scopinaro F, De Vincentis G, Banci M et al (1997) In vivo study of a technetium labelled anti-EGFr MoAB. Anticancer Res 17(3B):1761-1765 (Pubitemid 27263158)
161. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A (2006) The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 1766(1):120-139 (Pubitemid 44175636)
162. Sibler AP, Kempf E, Glacet A, Orfanoudakis G, Bourel D, Weiss E (1999) In vivo biotinylated recombinant antibodies: high efficiency of labelling and application to the cloning of active anti-human IgG1 Fab fragments. J Immunol Methods 224(1-2):129-140 (Pubitemid 29273987)
163. Signore A, Annovazzi A, Corsetti F et al (2002) Biological imaging for the diagnosis of inflammatory conditions. BioDrugs 16(4):241-259
164. Signore A, Chianelli M, Bei R, Oyen W, Modesti A (2003a) Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine. Eur J Nucl Med Mol Imaging 30(1):149-156 (Pubitemid 36692907)
165. Signore A, Capriotti G, Scopinaro F, Bonanno E, Modesti A (2003b) Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer. Trends Immunol 24(7):395-402 (Pubitemid 36830967)
166. Simon M, Rockl W, Hornig C et al (1998) Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/ VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol 9(6):1032-1044
167. Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM (2008) Site-specific, thiol-mediated conjugation of fluorescent probes to cysteinemodified diabodies targeting CD20 or HER2. Bioconjug Chem 19(12):2527-2534
168. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-712 (Pubitemid 19147683)
169. Slaughter TF, Achyuthan KE, Lai TS, Greenberg CS (1992) A microtiter plate transglutaminase assay utilizing 5-(biotinamido) pentylamine as substrate. Anal Biochem 205(1):166-171
170. Smith PA, Tripp BC, DiBlasio-Smith EA, Lu Z, LaVallie ER, McCoy JM (1998) A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in Escherichia coli. Nucleic Acids Res 26(6):1414-1420 (Pubitemid 28291615)
171. Steffen AC, Wikman M, Tolmachev V et al (2005) In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 20(3):239-248 (Pubitemid 41003829)
172. Styles JM, Harrison S, Gusterson BA, Dean CJ (1990) Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. Int J Cancer 45(2):320-324 (Pubitemid 20061388)
173. Summerer D, Chen S, Wu N, Deiters A, Chin JW, Schultz PG (2006) A genetically encoded fluorescent amino acid. Proc Natl Acad Sci USA 103(26):9785-9789 (Pubitemid 43993575)
174. Sunbul M, Yin J (2009) Site specific protein labeling by enzymatic posttranslational modification. Org Biomol Chem 7(17):3361-3371
175. Sundaresan G, Yazaki PJ, Shively JE et al (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow highcontrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44(12):1962-1969 (Pubitemid 40022142)
176. 99mTc-annexin V. J Nucl Med 46(5):807-815
177. Takahashi H, Nakada T, Nakaki M, Wands JR (1995) Inhibition of hepatic metastases of human colon cancer in nude mice by a chimeric SF-25 monoclonal antibody. Gastroenterology 108(1):172-182
178. Takasu S, Takahashi T, Okamoto S et al (2003) Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99mlabeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. J Neurooncol 63(3):247-256 (Pubitemid 36874008)
179. Taki M, Shiota M, Taira K (2004) Transglutaminase-mediated N- and C-terminal fluorescein labeling of a protein can support the native activity of the modified protein. Protein Eng Des Sel 17(2):119-126 (Pubitemid 38477738)
180. Tang Y, Wang J, Scollard DA et al (2005) Imaging of HER2/neupositive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 32(1):51-58 (Pubitemid 40187381)
181. Tirat A, Freuler F, Stettler T, Mayr LM, Leder L (2006) Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins. Int J Biol Macromol 39(1-3):66-76 (Pubitemid 44066539)
182. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ (2001) Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 248(1-2):47-66 (Pubitemid 32167024)
183. Tolmachev V, Nilsson FY, Widstrom C et al (2006) 111In-benzyl- DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47(5):846-853 (Pubitemid 46772889)
184. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7(4):555-568 (Pubitemid 46524679)
185. Tran T, Engfeldt T, Orlova A et al (2007) In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumortargeting affibody molecules. Bioconjug Chem 18(2):549-558 (Pubitemid 46493528)
186. Uhlen M, Nilsson B, Guss B, Lindberg M, Gatenbeck S, Philipson L (1983) Gene fusion vectors based on the gene for staphylococcal protein A. Gene 23(3):369-378 (Pubitemid 13009986)
187. Underiner TL, Ruggeri B, Gingrich DE (2004) Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 11(6):731-745 (Pubitemid 38380047)
188. Van den Eijnde SM, Boshart L, Reutelingsperger CP, De Zeeuw CI, Vermeij-Keers C (1997) Phosphatidylserine plasma membrane asymmetry in vivo: a pancellular phenomenon which alters during apoptosis. Cell Death Differ 4(4):311-316 (Pubitemid 27202217)
189. van den Eijnde SM, Boshart L, Baehrecke EH, De Zeeuw CI, Reutelingsperger CP, Vermeij-Keers C (1998) Cell surface exposure of phosphatidylserine during apoptosis is phylogenetically conserved. Apoptosis 3(1):9-16 (Pubitemid 128512000)
190. van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP (1996) A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24(2):131-139 (Pubitemid 26202924)
191. Velikyan I, Sundberg AL, Lindhe O et al (2005) Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46(11):1881-1888 (Pubitemid 46196651)
192. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D (1999) Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 59(2):347-352 (Pubitemid 29048866)
193. Volkmann G, Liu XQ (2009) Protein C-terminal labeling and biotinylation using synthetic peptide and split-intein. PLoS One 4(12):e8381
194. Voorzanger-Rousselot N, Garnero P (2007) Biochemical markers in oncology. Part I. Molecular basis. Part II. Clinical uses. Cancer Treat Rev 33(3):230-283 (Pubitemid 46767942)
195. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr (2005) Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 44(45):7342-7372 (Pubitemid 41689988)
196. Wang J, Xie J, Schultz PG (2006) A genetically encoded fluorescent amino acid. J Am Chem Soc 128(27):8738-8739 (Pubitemid 44061526)
197. Wang H, Cai W, Chen K et al (2007) A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 34(12):2001-2010 (Pubitemid 350212131)
198. Wang H, Chen K, Niu G, Chen X (2008) Site-specifically biotinylated VEGF121 for near-infrared fluorescence imaging of tumor angiogenesis. Mol Pharm 6(1):285-294
199. Ward ES, Ghetie V (1995) The effector functions of immunoglobulins: implications for therapy. Ther Immunol 2(2):77-94 (Pubitemid 26101857)
200. Weir AN, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson AD (2002) Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 30(4):512-516 (Pubitemid 35001587)
201. Weng KC, Noble CO, Papahadjopoulos-Sternberg B et al (2008) Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett 8(9):2851-2857
202. Wikman M, Steffen AC, Gunneriusson E et al (2004) Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 17(5):455-462 (Pubitemid 39294720)
203. Wikman M, Rowcliffe E, Friedman M et al (2006) Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnol Appl Biochem 45(Pt 2):93-105 (Pubitemid 44362494)
204. Wingfield P, Graber P, Shaw AR, Gronenborn AM, Clore GM, MacDonald HR (1989) Preparation, characterization and application of interleukin-1 beta mutant proteins with surfaceaccessible cysteine residues. Eur J Biochem 179(3):565-571 (Pubitemid 19062331)
205. Wolff C, Lai CS (1988) Evidence that the two amino termini of plasma fibronectin are in close proximity: a fluorescence energy transfer study. Biochemistry 27(9):3483-3487
206. Wolfgang WJ, Miller TW, Webster JM et al (2005) Suppression of Huntington's disease pathology in Drosophila by human singlechain Fv antibodies. Proc Natl Acad Sci USA 102(32):11563-11568 (Pubitemid 41153859)
207. Wong JY, Chu DZ, LE Williams et al (2006) A phase I trial of (90)YDOTA- anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm 21(2):88-100 (Pubitemid 43830430)
208. Wu AM, Chen W, Raubitschek A et al (1996) Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2(1):21-36 (Pubitemid 26096269)
209. Wu P, Shui W, Carlson BL et al (2009) Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc Natl Acad Sci USA 106(9):3000-3005
210. Xiao Y, Gao X, Taratula O et al (2009) Anti-HER2 IgY antibodyfunctionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells. BMC Cancer 9:351
211. Xie J, Schultz PG (2006) A chemical toolkit for proteins-an expanded genetic code. Nat Rev Mol Cell Biol 7(10):775-782 (Pubitemid 44450461)
212. Xiong JP, Stehle T, Zhang R et al (2002) Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 296(5565):151-155 (Pubitemid 34280076)
213. Xu MQ, Evans TC Jr (2005) Recent advances in protein splicing: manipulating proteins in vitro and in vivo. Curr Opin Biotechnol 16(4):440-446 (Pubitemid 41111531)
214. Xu R, Ayers B, Cowburn D, Muir TW (1999) Chemical ligation of folded recombinant proteins: segmental isotopic labeling of domains for NMR studies. Proc Natl Acad Sci USA 96(2):388-393 (Pubitemid 29061218)
215. Yang K, Basu A, Wang M et al (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 16(10):761-770 (Pubitemid 37442447)
216. Zhao J, Zhou Q, Wiedmer T, Sims PJ (1998) Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface. J Biol Chem 273(12):6603-6606 (Pubitemid 28160315)
217. Zou Y, Yin J (2009) Phosphopantetheinyl transferase catalyzed sitespecific protein labeling with ADP conjugated chemical probes. J Am Chem Soc 131(22):7548-7549